Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.
Ontology highlight
ABSTRACT: Ebola virus (EBOV) is a single-stranded RNA virus that causes Ebola virus disease (EVD), characterized by excessive inflammation, lymphocyte apoptosis, hemorrhage, and coagulation defects leading to multiorgan failure and shock. Recombinant vesicular stomatitis virus expressing the EBOV glycoprotein (VSV-EBOV), which is highly efficacious against lethal challenge in nonhuman primates, is the only vaccine that successfully completed a phase III clinical trial. Additional studies showed VSV-EBOV provides complete and partial protection to macaques immunized 7 and 3 days before EBOV challenge, respectively. However, the mechanisms by which this live-attenuated vaccine elicits rapid protection are only partially understood. To address this, we carried out a longitudinal transcriptome analysis
SUBMITTER: Menicucci AR
PROVIDER: S-EPMC6538780 | biostudies-literature | 2019 May
REPOSITORIES: biostudies-literature
ACCESS DATA